TNF-induced metalloproteinase-9 production is associated with neurological manifestations in HTLV-1-infected individuals

Mariele Guerra1, Natália B. Carvalho1, Silvane Santos2, Mauricio T. Nascimento3, Renata Sa1,3, Augusto M. Carvalho3, Edgar M. Carvalho1,3,4 and Lucas P. Carvalho1,3,4*

1Immunology Service, University Hospital Complex Professor Edgard Santos (C-HUPES), Federal University of Bahia (UFBA), Salvador, Bahia, Brazil, 2Biology Department, State University of Feira de Santana, Feira de Santana, Bahia, Brazil, 3Gonçalo Moniz Institute (IGM), Oswaldo Cruz Foundation Fundação Oswaldo Cruz (FIOCRUZ), Salvador, Bahia, Brazil, 4National Institute of Science and Technology - Tropical Diseases Conselho Nacional de Pesquisa/Ministério da Ciência e Tecnologia (CNPq/MCT), Salvador, Bahia, Brazil

HTLV-1-infected individuals may develop a neurologic inflammatory condition known as HTLV-1-associated myelopathy (HAM/TSP), in which the high production of TNF is observed. These patients exhibit higher proviral loads, enhanced production of proinflammatory cytokines and lymphocyte proliferation in comparison to asymptomatic HTLV-1 carriers and those presenting overactive bladder (OAB-HTLV-infected). Metalloproteinases (MMPs) are known to degrade the components of the blood-brain barrier, favoring the migration of infected cells into the central nervous system. Moreover, the unbalanced production of MMPs and their inhibitors (TIMPs) has also been associated with tissue damage. The present work studied the production of MMP-9 and TIMPs in HTLV-1-infected individuals with and without neurological manifestations. HAM/TSP patients presented higher concentrations of MMP-9 in peripheral blood mononuclear cell (PBMC) culture supernatants, as well as a higher MMP-9/TIMP-3 ratio when compared to the other groups studied. MMP-9 levels positively correlated with proviral load and TNF in OAB-HTLV-infected individuals, and the in vitro neutralization of TNF significantly decreased MMP-9 levels in PBMC culture supernatants. Our findings indicate an association between MMP-9 production and the proinflammatory state associated with HTLV-1 infection, as well as HAM/TSP.

KEYWORDS
HTLV-1, HAM/TSP, metalloproteinases, TIMPs, inflammation
Introduction

Approximately 10 million people are infected with HTLV-1 worldwide (1). Although most HTLV-1-infected individuals remain asymptomatic, some will develop neurological disorders, such as overactive bladder (OAB) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) (2–4). HAM/TSP is an inflammatory condition in which the principal neuropathological finding is chronic myelitis, characterized by parenchymal infiltration consisting mainly of lymphocytes (2–5). The mechanisms driving the development of HAM/TSP in HTLV-infected individuals are not well-understood. OAB, a urologic manifestation, and also characterized by increased urgency and frequency, as well as urinary loss (6–8). Although asymptomatic HTLV-1 carriers present urodynamic alterations, dysuria and urinary loss are more frequent among patients with severe HAM/TSP (9). Thus, it has been proposed that OAB may be an oligosymptomatic presentation of myelopathy, or an initial manifestation of HAM/TSP (10).

The host immune response against HTLV-1 is characterized by increased lymphocyte proliferation followed by exacerbated production of proinflammatory cytokines and chemokines, such as IFN-γ, TNF, CXCL-10. Patients with HAM/TSP produce higher levels of these molecules, and also present higher proviral loads compared to asymptomatic HTLV-1 carriers (11–15). TNF and CXCL-10 have been detected in cerebrospinal fluid (CSF), suggesting the potential for the virus to cross the blood-brain barrier (4, 16–19). The blood-brain barrier is composed of cells (astrocytes, pericytes, neurons and endothelial cells), while the extracellular matrix is formed by proteins, such as fibbers, collagen, elastin, laminin and fibronectin (16, 17, 20). The latter is responsible for permitting the entry of ions, molecules and cells into the central nervous system. However, in the context of pathologies, increased permeability of blood-brain barrier facilitates the entry of pathogens and infected cells into the central nervous system (16, 17).

Metalloproteinases (MMPs) are molecules that degrade extracellular matrix components. Unbalanced production between MMPs and their inhibitors (TIMPs) has been associated with tissue damage in several inflammatory conditions, including arthritis, cutaneous leishmaniasis, cancer and cardiovascular diseases (21–23). Among the MMPs, MMP-3 and -9 have been the focus of studies on HTLV due to their ability to degrade Types IV and V collagen, fibronectins and laminin, all components of the basement membrane in the blood-brain barrier (24–27). It has been documented that, when activated, astrocytes in the central nervous system produce pro-inflammatory cytokines, contributing to increased permeability in the blood-brain barrier (28). Moreover, astrocytes are also known to produce MMP-9 when in contact with HTLV-infected T cells (29). Moreover, MMP-9 has been evidenced in CSF, and MMP-9 production in the central nervous system has been hypothesized to be associated with HAM/TSP development (25, 29, 30). The literature contains several studies investigating imbalances in MMP and TIMP levels in serum and CSF in association with immunopathology in HTLV (24–26). However, since HTLV primarily infects T cell populations, we chose to focus on the production of MMP-9 and its TIMP-3 inhibitor by peripheral blood mononuclear cells (PBMC) in asymptomatic HTLV-1 carriers, HTLV-1-infected individuals with OAB (HTLV-1-OAB), and HAM/TSP patients. We found a relevant association between HAM/TSP and high levels of MMP-9, in addition to low levels TIMP-3. Moreover, TNF was identified as a key cytokine linked to MMP-9 production by PBMCs in HTLV-1-infected patients regardless of myelopathy.

Material and methods

Patients

The present study included 120 participants followed at the HTLV-1 multidisciplinary outpatient clinic at the Professor Edgard Santos University Hospital Complex of the Federal University of Bahia (HUPES-UFBA), Salvador, Bahia-Brazil. Subject participation was strictly voluntary, all individuals provided written informed consent and the present research protocol was submitted to and approved by the Institutional Review Board of the Federal University of Bahia. HTLV-1 infection was diagnosed through the detection of antibodies by ELISA (Cambridge Biotech Corp., Worcester, MA, USA) and subsequently confirmed by Western blot (HTLV blot 2.4, Genelab, Singapore). Participants were classified into three groups: i) HTLV-1 carriers (asymptomatic HTLV-1-infected individuals), ii) HTLV-1-OAB (HTLV-1-infected individuals with urinary manifestations indicative of neurogenic bladder, i.e., urgency or other urinary symptoms, such as nocturia and incontinence), iii) HAM/TSP (HTLV-1-infected individuals classified as definite HAM/TSP according to the de Castro-Costa diagnostic criteria (31). HTLV-1-infected individuals aged between 23-75 years of both genders participated in the study. Individuals coinfected with HIV, hepatitis virus (B or C), syphilis, and those using immunosuppressive drugs, or who were pregnant, were not recruited for this study. None of the studied patients were using corticosteroids.

Proviral load determination

DNA was extracted from 10⁶ PBMCs using proteinase K and salting-out method. HTLV-1 proviral load was quantified using a real-time TaqMan PCR method on an ABI Prism 7700 Sequence detector system (Applied Biosystems) (32). Five
plasmid dilution points were used to calculate the standard curve (pCHTLV-ALB). All samples were analyzed in duplicate, both for the quantification of HTLV-1 proviral load and albumin levels. Albumin DNA was used as an endogenous reference. Normalized HTLV-1 proviral load values were calculated using the ratio (HTLV-1 DNA average copy number/albumin DNA average copy number) × 2×10⁶, and expressed as the number of HTLV-1 copies per 10⁶ PBMCs.

Peripheral blood mononuclear cell cultures

Peripheral blood mononuclear cells were isolated from heparinized venous blood by Ficoll-Paque (GE Healthcare, Chicago, IL, USA) gradient centrifugation. After washing in saline, cell concentrations were adjusted to 3×10⁶ cells in 1 ml of RPMI-1640 medium (ThermoFisher Scientific, NY, USA) supplemented with 10% FBS (ThermoFisher Scientific, NY, USA), penicillin (100 U/mL) and streptomycin (100 µg/mL). PBMCs were dispensed into 24-well plates and incubated at 37°C under 5% CO₂ for 72 hours. Supernatants were collected from PBMCs cultures and stored at -70°C until the time of MMP-9, TIMP-3 and TNF quantification using an ELISA KIT (R&D Systems, Minneapolis, MS, USA), in accordance with manufacturer instructions. To investigate the effects of cytokine blockade on MMP-9 production, anti-TNF, anti-IFN-γ, anti-IL-1β, anti-IL-6 and anti-TGFβ (R&D Systems, Minneapolis, MS, USA) monoclonal antibodies were added to some PBMC cultures at a concentration of 10 µg/mL. Results are expressed in pg/mL.

Statistical analysis

Differences between groups were analyzed using the Mann-Whitney U test (for comparisons between two independent groups). Receiver operator characteristics (ROC) curve analysis was used to evaluate the ability of MMP-9 levels to distinguish between asymptomatic HTLV-1 carriers, HTLV-1-OAB individuals and HAM/TSP patients. Spearman’s rank correlation was employed to test correlations. All data were analyzed using GraphPad Prism 5.01 (GraphPad Software, San Diego, CA, USA). Differences were considered statistically significant when p value ≤ 0.05.

Results

Patients, proviral load and inflammatory response

The present study aimed to quantify MMP-9 and TIMP-3 production by PBMCs in HTLV-1-infected individuals with or without OAB, as well as in HAM/TSP patients. We enrolled 40 HTLV-1-infected asymptomatic individuals, 40 HTLV-1-OAB and 40 HAM/TSP patients. The studied groups did not differ with regards to sex or age (Table 1). Consistent with previous reports, proviral loads in HAM/TSP patients were significantly higher than in HTLV-1 asymptomatic carriers or HTLV-1-OAB patients (Table 1 and Supplementary Figure 1A) (12, 13). Also, as was previously documented, significantly higher spontaneous production of TNF was observed in PBMC culture supernatants from HAM/TSP patients compared to HTLV-1 carriers or HTLV-1-OAB patients (Table 1 and Supplementary Figure 1B) (12, 14, 16).

Unbalanced production of MMP9 and TIMP3 in HAM/TSP patients

HAM/TSP development in HTLV-infected patients has been associated with the infiltration of leukocytes into the central nervous system. Several studies have documented the association of MMP-9 production in CSF with blood-brain barrier disruption (33, 34). Therefore, we assessed the concentrations of MMP-9 and TIMP-3 in PBMC culture supernatants from HTLV-1-infected individuals. MMP-9 levels were found to be significantly higher in PBMC cultures from HAM/TSP patients compared to HTLV-1 carriers and HTLV-1-OAB individuals (Figure 1A). MMP-9 activity is inhibited by TIMPs (22, 26, 35). Moreover, lower TIMP-3 levels were associated with HAM/TSP development.

TABLE 1 Clinical and demographical characteristics of studied groups.

|                  | Asymptomatic (n=40) | OAB-HTLV (n=40) | HAM/TSP (n=40) | P value |
|------------------|---------------------|-----------------|---------------|---------|
| Female           | 27 (67%)            | 28 (70%)        | 29 (72%)      | 0.74*   |
| Age (years)      | 50 (25-69)          | 55 (25-71)      | 55 (23-75)    | 0.33**  |
| Viral load (copies/10⁶ cells) | 31085 (0.757662) | 111275 (0.992164) | 150622 (0.1768442) | <0.05*** |
| TNF (pg/ml)      | 99 (0.3956)         | 504 (0.3956)    | 1043 (0.4880) | <0.05*** |

*Fisher test (t²).
**Mann Whitney test.
*aDifferences between HAM/TSP and other groups.
levels were observed in HAM/TSP patients compared to the other HTLV-1-infected individuals (Figure 1B). Finally, the unbalanced production of MMP-9 and TIMP-3 was evidenced in HAM/TSP patients via higher MMP-9/TIMP3 ratios compared to HTLV-1 carriers and HTLV-1-OAB individuals (Figure 1C). ROC analysis confirmed that the ability of MMP-9 to distinguish between HAM/TSP patients and asymptomatic HTLV-1 carriers, as well as HTLV-1-OAB patients, with high accuracy (Figures 2A, B).

MMP-9 levels correlate with inflammatory response and proviral load in OAB-HTLV-1 patients

Proviral load has been associated with an exacerbated inflammatory response and HAM/TSP development (12, 14). To study the association between MMP-9 production and neurological manifestations associated with HTLV-1 infection, we investigated whether MMP-9 levels correlated with proviral load and TNF production. Our results showed a positive correlation between MMP-9 production with proviral load and TNF production in OAB patients, indicating the association of MMP-9 with the immunopathology and neurological manifestation (Figure 3).

TNF induces MMP-9 production in HTLV

The present results indicate that HAM/TSP patients produce higher levels of TNF compared to asymptomatic or OAB-HTLV-infected individuals. Furthermore, it has been documented that TNF induces MMP-9 production (36, 37). To investigate the effect of TNF levels on MMP-9 production in HTLV-1, we cultured PBMCs from HTLV-1-infected individuals in the presence of anti-TNF antibodies. The neutralization of TNF decreased the spontaneous production of MMP-9 in PBMC culture supernatants (Figure 4). Other cytokines, such as IFN-γ, IL-1-β, IL-6 and TGF-β, are also known to affect MMP-9 production (38, 39). Our results...
indicate a protective role for IFN-γ, since the neutralization of this cytokine subsequently increased MMP-9 production in PBMC culture supernatants (Figure 4). Together, these findings demonstrate that proviral load influences proinflammatory response, which is linked to both the production of MMP-9 and HAM/TSP development.

**Discussion**

Patients with HAM/TSP present high proviral load, and HTLV-1-infected T cells from these individuals produce high levels of proinflammatory mediators, e.g., TNF and CXCL-10, when compared to asymptomatic carriers or OAB-HTLV-1-infected individuals.
infected individuals (14). The development of HAM/TSP is associated with the migration of T cells across the blood-brain barrier, composed of endothelial cells that selectively coordinate cell migration (5, 16, 17). Thus, increased permeability in the blood-brain barrier allows for the infiltration of inflammatory cells into the central nervous system (16, 17). Under such conditions, MMPs can actively damage the blood-brain barrier, and MMP-9 has been shown to be an important mediator in this process (40). For instance, increased levels of MMP-9 are found after stroke (33, 34). MMP-9 is mainly secreted by neutrophils, mononuclear phagocytes and fibroblasts (35, 41). Since the presently performed experiments employed PBMCs, it is likely that monocytes are the main source of MMP-9. However, other cell types also contribute to the production of MMP-9, as it has been shown that HTLV-1-infected CD4+ T cells induce astrocytes to produce MMP-9, and another study demonstrated that HTLV-1-infected cells are prone to produce MMP-9 through the transactivation of its gene by the viral Tax protein (29, 42). Our data indicate the low production of TIMP-3 in HAM/TSP patients. Imbalance in the production of MMPs/TIMPs can lead to excessive degradation of the extracellular matrix, as well as changes in the interconnectivity of the cells that make up the blood brain barrier (25). Thus, alterations in the balance of MMP/TIMP production appear to be relevant in neurological diseases mediated by T lymphocytes. Additionally, we found that MMP-9 levels correlated positively with proviral load, which supports the hypothesis that MMP-9 participates in a deleterious inflammatory response.

TNF, a proinflammatory cytokine produced during viral infection, can stimulate monocytes to secrete MMPs (23, 25). In HTLV-infected individuals, it has been demonstrated that HTLV-infected cells produce TNF and other proinflammatory cytokines/chemokines through the nuclear translocation of NF kappa B components, mediated by the viral Tax protein (43). Our data show that the HAM/TSP patients studied herein produce more TNF than asymptomatic carriers or OAB-HTLV-infected patients, suggesting the contribution of this cytokine to the immunopathogenesis of HAM/TSP. Moreover, our results also show that MMP-9 production in HTLV1-infected patients is partially dependent on TNF. We further identified a strong positive correlation between MMP-9 and TNF in OAB individuals, despite the lack of such a correlation in patients with HAM/TSP. It is possible that the similar MMP-9 levels found among the HAM/TSP individuals, in contrast to OAB, contributed to the lack of a correlation between MMP-9 and TNF in this group. Furthermore, as most HAM/TSP patients present high proviral load, it is known that the viral Tax protein directly induces MMP-9 production, which may abrogate the effects of TNF in HAM/TSP patients (44). The use of etanercept, a TNF inhibitor, has been shown to reduce MMP-9 levels in children with polyarticular juvenile idiopathic arthritis, corroborating the role of TNF in MMP-9 production (45). Although TNF possesses antiviral properties, in the context of HTLV infection, its production does not seem to contribute to viral killing, as TNF has been observed to positively correlate with proviral load (46–48). Further, HTLV-1-infected individuals treated with etanercept did not present any worsening of HTLV-associated T cell leukemia over a five-year period (49). Altogether, these results support the notion that HTLV-infected individuals may benefit from treatments designed to attenuate TNF production.

Some works have reported increased levels of MMP-9 in the central nervous system in individuals with HAM/TSP (26, 50, 51). However, our findings also indicate a strong correlation between TNF and MMP-9 production in OAB-HTLV-infected patients. We were able to clearly identify two groups of MMP-9 producers (high and low producers) among the asymptomatic and OAB individuals studied. OAB individuals presenting neurological manifestations are believed to eventually progress to HAM/TSP.

The present results were achieved via a cross-sectional study, which presents limitations. As HAM/TSP is an insidious complication of HTLV infection, long-term cohort studies are necessary to definitively validate the link between TNF and MMP-9 production in the context of HAM/TSP development. In conclusion, our findings enhance the data available in the literature by shedding light on the association between unbalanced production of MMP-9 and TIMP-3 by PBMCs and the development of HAM/TSP, and also serve to highlight the important role of TNF in triggering pathologic responses in HTLV infection. The identification of pathways involved in the immunopathogenesis of HTLV-1-associated diseases may aid in the quest to discover novel therapeutic approaches.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Materials. Further inquiries can be directed to the corresponding author.

Ethics statement

The studies involving human participants were reviewed and approved by School of Medicine, Federal University of Bahia. The patients/participants provided their written informed consent to participate in this study.

Author contributions

MG, NC, SS, EC, and LC participated in the study design. MG, NC, SS, AC, EC, and LC drafted the manuscript. MG, MN, NC, and RS performed the experiments. All authors contributed to the article and approved the submitted version.
Funding

FAPESP and CNPq - Instituto Nacional de Ciências e Tecnologia para Doenças Tropicais (INCT-DT) Project number: 573839/2008-5 – INCT-DT.

Acknowledgments

We thank the staff of HTLV-1 clinic at the Professor Edgard Santos University Hospital Complex (HUPES-UFBA). The authors would like to thank Andris K. Walter for critical analysis, English language revision and manuscript copyediting assistance.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Gessain A, Casar O. Epidemiological aspects and world distribution of HTLV-I infection. Front Microbiol (2012) 3:388. doi: 10.3389/fmicb.2012.00388
2. Bangham CR. The immune response to HTLV-I. Curr Opin Immunol (2000) 12:397–402. doi: 10.1016/S0952-7915(00)00107-2
3. Edlich RF, Arnette JA, Williams FM. Global epidemic of human T-cell lymphotropic virus type-I (HTLV-I). J Emerg Med (2000) 18:109–19. doi: 10.1016/S0736-4679(99)00173-0
4. Gudo ES, Silva-Barbosa SD, Linhares-Lacerda L, Ribeiro-Alves M, Real SC, Bou-Habib DC, et al. HTLV-1/HTLV-2-derived T cell lines promote morphological and functional changes in human astrocytes cell lines: Possible role in the enhanced T cells recruitment into central nervous system. Viral J (2015) 12:165. doi: 10.1186/s12895-015-0398-x
5. Banerjee S, Bhat MA. Neuron-glial interactions in blood-brain barrier formation. Ann Rev Neurosci (2007) 30:235–58. doi: 10.1146/annurev.neuro.30.051606.094345
6. Castro NM, Freitas DM, Rodrigues W Jr., Muniz A, Oliveira P, Carvalho EM. Urodynamic features of the voiding dysfunction in HTLV-I infected individuals. Int Braz J Urol. (2007) 33:238-44. doi: 10.1590/S1677-55382007000200016
7. Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL. Global epidemiology of HTLV-I infection and associated diseases. Oncogene (2005) 24:6058–68. doi: 10.1038/sj.onc.1208968
8. Rocha PN, Rehem AP, Santana JF, Castro N, Muniz AL, Salgado K, et al. The cause of urinary symptoms among human T lymphotropic virus type I (HTLV-I) infected patients: a cross sectional study. BMC Infect Dis (2007) 7:15. doi: 10.1186/1471-2334-7-15
9. Castro NM, Rodrigues W Jr., Freitas DM, Muniz A, Oliveira P, Carvalho EM. Urinary symptoms associated with human T-cell lymphotropic virus type I infection: Evidence of urinary manifestations in large group of HTLV-I carriers. Urology (2007) 69:813–8. doi: 10.1016/j.urology.2007.01.052
10. Oliveira P, Castro NM, Carvalho EM. Urinary and sexual manifestations of patients infected by HTLV-I. Clinics (Sao Paulo) (2007) 62:191–6. doi: 10.1590/S1807-59322007000200015
11. Prince HE, York J, Golding I, Owen SM, Lal RB. Spontaneous lymphocyte proliferation in human T-cell lymphotropic virus type I (HTLV-I) and HTLV-II infection: T-cell subset responses and their relationships to the presence of provirus and viral antigen production. Clin Diag Lab Immunol (1994) 1:273–82. doi: 10.1128/cdii.1.3.273-282.994
12. Guerra M, Luna T, Souza A, Amorim C, Carvalho NB, Carvalho L, et al. Local and systemic production of proinflammatory chemokines in the pathogenesis of HAM/TSP. Cell Immunol (2018) 354:70–7. doi: 10.1016/j.cellimm.2018.09.009
13. Nagai M, Usuku K, Matsumoto W, Kodama D, Takenouchi N, Moritoyo T, et al. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol. (1998) 4:866–93. doi: 10.1038/sj.onc.1208968
14. Santos SB, Porto AF, Muniz AL, de Jesus AR, Magalhaes E, Melo A, et al. Exacerbated inflammatory cellular immune response characteristics of HAM/TSP is observed in a large proportion of HTLV-I asymptomatic carriers. BMC Infect Dis (2004) 4:7. doi: 10.1186/1471-2334-4-7
15. Grassi ME, Olavarria VN, Kruschewsky Rde A, Mascarenhas RE, Dourado J, Correia LC, et al. Human T cell lymphotropic virus type I (HTLV-I) proviral load of HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients according to new diagnostic criteria of HAM/TSP. J Med Virol (2011) 83:1269–74. doi: 10.1002/jmv.22087
16. Afonso PV, Orden S, Cumont MC, Seillan D, Cartier L, Rezaie P, et al. Alteration of blood-brain barrier integrity by retroviral infection. PloS Pathog (2008) e1000205. doi: 10.1371/journal.ppat.1000205
17. Afonso PV, Orden S, Prerost MC, Schmitt C, Seillan D, Weksler B, et al. Human blood-brain barier disruption by retroviral infected lymphocytes. role of myosin light chain kinase in endothelial tight-junction disorganization. J Immunol (2007) 179:2576–83. doi: 10.4049/jimmunol.179.4.2576
18. Nakamura S, Nagano I, Yoshioka M, Shimazaki S, Onodera J, Kogure K. Detection of tumor necrosis factor-alpha-positive cells in cerebrospinal fluid of patients with HTLV-I-associated myelopathy. J Neurommunol. (1993) 42:127-30. doi: 10.1016/0165-5728(93)90001-F
19. Tamaki K, Sato T, Tsugawa J, Fujioka S, Yagishita N, Araya N, et al. Cerebrospinal fluid CXCL10 as a candidate surrogate marker for HTLV-I-Associated Myelopathy/Tropical spastic paraparesis. Front Microbiol (2019) 10:2210. doi: 10.3389/fmicb.2019.02210
20. Osame M. Pathological mechanisms of human T-cell lymphotropic virus type I-associated myelopathy (HAM/TSP). J Neurovirol. (2002) 8:359–64. doi: 10.1038/sj.onc.1208968

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.954103/full#supplementary-material

Supplementary figure 1
Increased proviral load and high TNF production in HAM/TSP patients. (A) Proviral load values from HTLV-I carriers, OAB-HTLV-1-infected and HAM/TSP patients, as assayed by PCR. (B) PBMCs from HTLV-1 carriers, OAB-HTLV-1-infected and HAM/TSP patients were cultured for 72h, after which TNF levels were assessed by ELISA. Bars represent median values from each group. Nonparametric testing (Mann-Whitney) was used to compare among groups.
21. McCawley LJ, Matrisian LM. Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today (2000) 6:149–56. doi: 10.1016/S1357-4303(00)01686-5

22. Murphy G, Nagase H. Progress in matrix metalloproteinase research. Mol Asp Med (2008) 29:290–308. doi: 10.1016/j.mam.2008.05.002

23. Campos TM, Passos ST, Novaes FO, Britto DP, Costa RS, Queiroz A, et al. Matrix metalloproteinases 9 production by monocytes is enhanced by TNF and participates in the pathology of human cutaneous leishmaniasis. PLoS Negl Trop Dis (2014) 8:e3282. doi: 10.1371/journal.pntd.0003282

24. Biddison WE, Kubota R, Kawashita T, Taub DH, Cruikshank WW, Center DM, et al. Human T-cell leukemia virus type I (HTLV-I)-specific CD8+ T-Clon from patients with HTLV-I-associated neurologic disease secretes proinflammatory cytokines, chemokines, and matrix metalloproteinases. J Immunol (1997) 159:2018–25.

25. Giraudon P, Buart S, Bernard A, Belin MF. Cytokines secreted by glial cells infected with HTLV-1 modulate the expression of matrix metalloproteinases (MMPs) and their natural inhibitor (TIMPs): Possible involvement in neurodegenerative processes. Mol Psychiatry (1997) 2:107–10. doi: 10.1038/sj.mp.4000218

26. Giraudon P, Buart S, Bernard A, Thomasset N, Belin MF. Extracellular matrix remodeling metalloproteinases and inhibition of the central nervous system with retrovirus human T-lymphotropic virus type I (HTLV-I). Prog Neurobiol (1996) 49:169–84. doi: 10.1016/0003-0820(96)00017-2

27. Vasse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ Res (2003) 92:827–39. doi: 10.1161/01.RES.0008070112.80711.3D

28. Nair A, Frederick TJ, Miller SD. Astrocytes in multiple sclerosis: a product of their environment. Cell Mol Life Sci (2008) 65:2702–20. doi: 10.1007/s00018-008-8059-5

29. Giraudon P, Smyrocha R, Buart S, Bernard A, Cartier L, Belin MF, et al. T-Lymphocytes activated by persistent viral infection differentially modify the expression of metalloproteinases and their endogenous inhibitors, TIMPs, in human astrocytes: Relevance to HTLV-I-induced neurological disease. J Immunol (2000) 164:2718–27. doi: 10.4049/jimmunol.164.5.2718

30. Giraudon P, Vernant JC, Confavreux C, Belin MF, Desgranges C. Matrix metalloproteinase 9 (gelatinase b) in cerebrospinal fluid of HTLV-i-infected T-cell lines and primary adult T-cell leukemia cells. Blood (2002) 100:1828–34. doi: 10.1182/blood.2002-01-0151

31. De Castro-Costa CM, Araujo AQ, Barreto MM, Takayanagui OM, Sohler JC e l lP h y s i o l J Immunobiology (1995) 1:193–8. doi: 10.1007/BF02895538

32. Mori N, Sato H, Hayashihara T, Senba M, Hayashi T, Yamada Y, et al. Human T-cell leukemia virus type I tax transactivates the matrix metalloproteinase-9 gene: potential role in mediating adult T-cell leukemia invisiveness. Blood (2002) 99:1341–9. doi: 10.1182/blood.V99.8.1341

33. Basic J, Pavlovic D, Jevtovic-Stoimenov T, Vojinovic J, Susic G, Stojanovic I, et al. Etanercept reduces matrix metalloproteinase-9 level in children with polyarticular juvenile idiopathic arthritis and TNF-alpha-308GG genotype. J Biol Chem (2001) 276:653–70. doi: 10.1074/jbc.M009416200

34. Munion E, Israel A. Activation of NF-kappa b by the tax protein of HTLV-1. Immunobiology (1995) 193:128–36. doi: 10.1007/BF0271-2985(11)00538-5

35. Murphy G, Nagase H. Progress in matrix metalloproteinase research. Mol Asp Med (2008) 29:290–308. doi: 10.1016/j.mam.2008.05.002

36. Lee JT, Lin CC, Wu YC, Yang CM. TNF-alpha induces matrix metalloproteinase-9 expression in A549 cells: role of TNF receptors/PKCalpha-dependent signaling pathways. J Cell Physiol (2010) 224:654–64. doi: 10.1002/jcp.22142

37. Kotlari P, Pestana R, Mesaura R, Elchahi R, Khan KM, Dannenberg AJ, et al. IL-6-mediated induction of matrix metalloproteinase-9 is modulated by JAK-dependent IL-10 expression in macrophages. J Immunol (2014) 192:349–57. doi: 10.4049/jimmunol.1301906

38. Li DQ, Lokeshwar BL, Solomon A, Monroy D, Ji Z, Pfafflecider SC. Regulation of MMP-9 production by human corneal epithelial cells. Exp Eye Res (2001) 73:449–58. doi: 10.1006/exer.2000.5880

39. Murphy G, Docherty AJ. The matrix metalloproteinases and their inhibitors. Brain Res (1998) 842:92–100. doi: 10.1016/S0006-8993(98)01434-0

40. Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone FC. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke (1998) 29:1020–30. doi: 10.1161/01.STR.29.5.1020

41. Murphy G, Docherty AJ. The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol (1992) 7:120–5. doi: 10.1165/ajrccm/7.2.120